Bioavailability of Dienogest 2.0 mg With Regards to Reference Product

Laboratorios Andromaco

Status and phase

Completed

Phase 1

Conditions

Bioequivalence

Treatments

Drug: Dienogest 2.0 mg Test Drug

Drug: Dienogest 2.0 mg Reference Product

Study type

Interventional

Funder types

Industry

Identifiers

NCT04230083

HP8820-01

Details and patient eligibility

About

This Pivotal study will investigate the bioavailability in women of 1 tablet formulations containing Dienogest 2.0 mg. The Pivotal study will be performed at a single site with 30 subjects. Participants will take 1 tablet of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.

Full description

The primary objective of the study is to investigate the relative bioavailability of Dienogest of 1 tablet formulation with Dienogest 2.0 mg and to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:

Test Product: Product manufactured by Laboratorios Andrómaco S.A.
Reference Product: Visannette [Trademark], product of Bayer AG, Germany. The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters area under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to 72 hours (AUC0-72), and maximum plasma concentration (Cmax) for total Dienogest will be determined. Participants will be confined in the study site for approximately 36 hours during each study period (for 12 hours pre-dosing and for 24 hours post dosing) during which pharmacokinetic (PK) blood samples will be obtained. 16 blood samples will be taken up to 24 hours after the administration in each period. Participants will return to the site to provide additional blood samples at 48 h, and 72 h postdose.

The washout period between the two study periods will be at least 14 days. The samples from each participant will be analyzed with 2 methods of highperformance liquid chromatography-tandem mass spectrometry bioanalytical assays to quantify total Dienogest in plasma.

The safety objective is to evaluate the tolerability of both formulations in women by collecting adverse events.

Enrollment

30 patients

Sex

Female

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Non-pregnant and non-breastfeeding women
Women of childbearing age with an acceptable form of contraception during the study
18 to 55 years old inclusive; BMI greater than or equal to 18.51 and less than or equal to 29.99
Non-smoking or smoke only 3 cigarettes every 7 days
With results of laboratory tests, electrocardiogram and chest radiography in normal and / or negative or abnormal ranges but without clinical relevance and declared suitable for study by the doctor after the physical examination
Capable to understand the Informed Consent Form

Exclusion criteria

Study site or sponsor staff or family members
With history of drug and/or alcohol abuse
Smokers more tan 3 cigarettes every 7 days
Vitamin supplements intake 7 days prior to the administration of the medications under study
Any recent change in eating habits or physical exercise
Using of a pharmacological therapy (except over the counter medication use 7 days prior to the study)
Hypersensitivity to the study drug or to other chemically related compounds, history of serious adverse reactions or hypersensitivity to any medication
Use, during the 28 days prior to the start of the study, of medications known to alter liver enzyme activity
Consumption of beverages or food containing grapefruit or pink grapefruit, within 7 days prior to each administration of the study medication and consumption of alcohol, caffeine or beverages or foods containing xanthines 24 hours before each administration of the study medication until the last sample of each period
History of any significant cardiovascular disease
Acute disease that generates significant physiological changes from the time of selection until the end of the study
HIV, Hepatitis B and/or C positive
Presence or history of thrombophlebitis, thrombosis or thromboembolic disorders, deep vein thrombosis, pulmonary embolism or known coagulopathy.
Donation or loss of a significant volume (more than 100 mL) of blood or plasma or platelets during the 3 months prior to the start of the study
Subjects who have participated in any type of clinical study during the 3 months prior to the start of the study
History of any gastrointestinal surgery that could affect drug absorption
Presence of fainting history or fear to blood collection